Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Table 2 Effect of cisplatin (CP) and different treatments of AHE on liver biomarkers in serum

Group	ALT (U/l)	AST (U/l)	ALP (U/l)	LDH (U/l)
Control	44.63 ± 0.49 ^b	72.83 ± 0.12^b	120.7 ± 0.33 ^b	70.50 ± 1.04^b
CP	138.3 ± 0.29^a	192.4 ± 0.35^a	350.0 ± 0.58 ^a	92.83 ± 0.60^a
AHE alone	44.57 ± 0.23^b	72.63 ± 0.19 ^b	120.9 ± 0.21^b	70.33 ± 0.67^b
CP + AHE	101.8 ± 0.28^{a, b, d}	140.4 ± 0.30 ^{a, b, d}	299.2 ± 0.42^{a, b, d}	84.67 ± 0.67^{a, b, d}
AHE + CP	46.60 ± 0.31^{a, b, c}	75.97 ± 0.55^{a, b, c}	135.8 ± 0.28^{a, b, c}	76.30 ± 0.35^{a, b, c}
CP + Sily	47.17 ± 0.17^{a**, b}	75.53 ± 0.53 ^{a, b}	134.0 ± 0.55^{a, b}	73.50 ± 0.50^b

Values expressed as mean ± SEM
^a Significance at p < 0.0001 Vs. control group
^b Significance at p < 0.0001 Vs. Cisplatin (CP) group
^c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
^d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
^** Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)